Trial Profile
MJR-35 long-term study to investigate the safety and efficacy in patients with dysmenorrhea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Dienogest (Primary)
- Indications Dysmenorrhoea
- Focus Adverse reactions; Registrational
- Sponsors Mochida Pharmaceutical
- 01 Apr 2020 Status changed to completed as per results published in the Journal of Obstetrics and Gynaecology Research
- 05 Jun 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 01 Apr 2017 New trial record